Kosten-nutzwert-analyse der kontrastverstärkten MR-angiographie mit automatischem tischvorschub zur diagnose und therapieplanung bei peripherer arterieller verschlusserkrankung

Translated title of the contribution: Cost-utility analysis of contrast-enhanced MR angiography with automated table-translation for diagnosis and therapy planning in patients with peripheral vascular disease

T. Meindl, K. Berger, Friedrich D Knollmann, H. Zurbrügg, J. Mäurer

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: To analyze the cost-utility of contrast-enhanced MR angiography (ceMRA) in the diagnosis and the planning of surgical or interventional treatment in patients with peripheral arterial occlusive disease. Materials and Methods: Additional costs and incremental costs per quality-adjusted life-year for ceMRA were calculated by a decision model. The costs of ceMRA and conventional angiography were compared. Treatment was either surgery or PTA. A retrospective analysis of 24 patients provided the data for the diagnostic accuracy of ceMRA. The data about quality of life assessment were taken from the literature. Costs were calculated in Euro using the current fee schedule. The influence of the individual parameters on the model was estimated from a sensitivity analysis. Results: Per quality-adjusted life-year, ceMRA added € 24,408.60 in cases undergoing radiologic intervention and € 24,191.32 in cases treated surgically. Conclusion: Despite its high costs, ceMRA is an effective diagnostic procedure considering patient benefits. Additional costs do not exceed an acceptable range.

Original languageGerman
Pages (from-to)981-990
Number of pages10
JournalRoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren
Volume175
Issue number7
DOIs
StatePublished - Jul 1 2003
Externally publishedYes

Fingerprint

Peripheral Vascular Diseases
Cost-Benefit Analysis
Angiography
Costs and Cost Analysis
Quality-Adjusted Life Years
Therapeutics
Fee Schedules
Arterial Occlusive Diseases
Peripheral Arterial Disease
Quality of Life

Keywords

  • Arteries, extremities
  • Arteries, stenosis or obstruction
  • Cost-utility analysis
  • Economics, medical
  • Magnetic resonance (MR)
  • Vascular studies

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

@article{0cbf983457c743a3bd4f86317a6b6457,
title = "Kosten-nutzwert-analyse der kontrastverst{\"a}rkten MR-angiographie mit automatischem tischvorschub zur diagnose und therapieplanung bei peripherer arterieller verschlusserkrankung",
abstract = "Purpose: To analyze the cost-utility of contrast-enhanced MR angiography (ceMRA) in the diagnosis and the planning of surgical or interventional treatment in patients with peripheral arterial occlusive disease. Materials and Methods: Additional costs and incremental costs per quality-adjusted life-year for ceMRA were calculated by a decision model. The costs of ceMRA and conventional angiography were compared. Treatment was either surgery or PTA. A retrospective analysis of 24 patients provided the data for the diagnostic accuracy of ceMRA. The data about quality of life assessment were taken from the literature. Costs were calculated in Euro using the current fee schedule. The influence of the individual parameters on the model was estimated from a sensitivity analysis. Results: Per quality-adjusted life-year, ceMRA added € 24,408.60 in cases undergoing radiologic intervention and € 24,191.32 in cases treated surgically. Conclusion: Despite its high costs, ceMRA is an effective diagnostic procedure considering patient benefits. Additional costs do not exceed an acceptable range.",
keywords = "Arteries, extremities, Arteries, stenosis or obstruction, Cost-utility analysis, Economics, medical, Magnetic resonance (MR), Vascular studies",
author = "T. Meindl and K. Berger and Knollmann, {Friedrich D} and H. Zurbr{\"u}gg and J. M{\"a}urer",
year = "2003",
month = "7",
day = "1",
doi = "10.1055/s-2003-40433",
language = "German",
volume = "175",
pages = "981--990",
journal = "Aktuelle Radiologie",
issn = "1433-5972",
publisher = "Georg Thieme Verlag",
number = "7",

}

TY - JOUR

T1 - Kosten-nutzwert-analyse der kontrastverstärkten MR-angiographie mit automatischem tischvorschub zur diagnose und therapieplanung bei peripherer arterieller verschlusserkrankung

AU - Meindl, T.

AU - Berger, K.

AU - Knollmann, Friedrich D

AU - Zurbrügg, H.

AU - Mäurer, J.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Purpose: To analyze the cost-utility of contrast-enhanced MR angiography (ceMRA) in the diagnosis and the planning of surgical or interventional treatment in patients with peripheral arterial occlusive disease. Materials and Methods: Additional costs and incremental costs per quality-adjusted life-year for ceMRA were calculated by a decision model. The costs of ceMRA and conventional angiography were compared. Treatment was either surgery or PTA. A retrospective analysis of 24 patients provided the data for the diagnostic accuracy of ceMRA. The data about quality of life assessment were taken from the literature. Costs were calculated in Euro using the current fee schedule. The influence of the individual parameters on the model was estimated from a sensitivity analysis. Results: Per quality-adjusted life-year, ceMRA added € 24,408.60 in cases undergoing radiologic intervention and € 24,191.32 in cases treated surgically. Conclusion: Despite its high costs, ceMRA is an effective diagnostic procedure considering patient benefits. Additional costs do not exceed an acceptable range.

AB - Purpose: To analyze the cost-utility of contrast-enhanced MR angiography (ceMRA) in the diagnosis and the planning of surgical or interventional treatment in patients with peripheral arterial occlusive disease. Materials and Methods: Additional costs and incremental costs per quality-adjusted life-year for ceMRA were calculated by a decision model. The costs of ceMRA and conventional angiography were compared. Treatment was either surgery or PTA. A retrospective analysis of 24 patients provided the data for the diagnostic accuracy of ceMRA. The data about quality of life assessment were taken from the literature. Costs were calculated in Euro using the current fee schedule. The influence of the individual parameters on the model was estimated from a sensitivity analysis. Results: Per quality-adjusted life-year, ceMRA added € 24,408.60 in cases undergoing radiologic intervention and € 24,191.32 in cases treated surgically. Conclusion: Despite its high costs, ceMRA is an effective diagnostic procedure considering patient benefits. Additional costs do not exceed an acceptable range.

KW - Arteries, extremities

KW - Arteries, stenosis or obstruction

KW - Cost-utility analysis

KW - Economics, medical

KW - Magnetic resonance (MR)

KW - Vascular studies

UR - http://www.scopus.com/inward/record.url?scp=0041367355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041367355&partnerID=8YFLogxK

U2 - 10.1055/s-2003-40433

DO - 10.1055/s-2003-40433

M3 - Article

VL - 175

SP - 981

EP - 990

JO - Aktuelle Radiologie

JF - Aktuelle Radiologie

SN - 1433-5972

IS - 7

ER -